Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
Aptinyx Inc. (Nasdaq: APTX) announced its participation in the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The fireside chat will be available on-demand starting 6:00 AM ET on January 11, through the H.C. Wainwright conference portal. Additionally, a webcast will be accessible on the 'Events and Presentations' page of the company's website, archived for 30 days post-event. Aptinyx focuses on developing therapies for brain and nervous system disorders, with three product candidates in clinical development.
- None.
- None.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021.
The fireside chat will be available on-demand through the H.C. Wainwright conference portal, beginning at 6:00 AM ET on Monday, January 11, 2021.
A webcast will also be available on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005274/en/
FAQ
When is Aptinyx participating in the H.C. Wainwright BioConnect 2021 Conference?
What time will the Aptinyx fireside chat be available?
Where can I watch the Aptinyx webcast?
How long will the Aptinyx webcast be available after the conference?
What is the focus of Aptinyx's research and development?
